S&P Futures
4,154.25 -37.25 (-0.89%) Dow Futures
33,968.00 -129.00 (-0.38%) Nasdaq Futures
12,640.00 -206.75 (-1.61%) Russell 2000 Futures
2,003.70 -4.20 (-0.21%) Crude Oil
75.66 -0.22 (-0.29%) Gold
1,924.10 -6.70 (-0.35%)
Protalix BioTherapeutics, Inc. (PLX)
After hours:
Chart Events
Performance Outlook
| Previous Close | 1.6200 |
| Open | 1.6700 |
| Bid | 1.5800 x 800 |
| Ask | 1.6400 x 800 |
| Day's Range | 1.6100 - 1.6800 |
| 52 Week Range | 0.7000 - 2.0000 |
| Volume | |
| Avg. Volume | 507,683 |
| Market Cap | 82.585M |
| Beta (5Y Monthly) | 1.49 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.5350 |
| Earnings Date | Mar 29, 2023 - Apr 03, 2023 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for PLX
Related Research
- Protalix BioTherapeutics, Inc.Daily – Vickers Top Buyers & Sellers for 01/06/2023The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.RatingFair ValueEconomic Moat28 days agoArgus Research
- PR Newswire
Protalix BioTherapeutics Issues 2023 Letter to Stockholders
Protalix BioTherapeutics, Inc. (NYSE American: PLX) (TASE: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell based protein expression system, today announced the following letter from its President and Chief Executive Officer, Dror Bashan, to its stockholders and the investment community.
- PR Newswire
Protalix BioTherapeutics to Delist its Common Stock from the Tel Aviv Stock Exchange
Protalix BioTherapeutics, Inc. (NYSE American: PLX) (TASE: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell based protein expression system, announced today that the Company's management and Board of Directors have decided that it is in the best interest of the Company to voluntarily delist its common stock from the Tel Aviv Stock Exchange (the "TASE").
- PR Newswire
Protalix BioTherapeutics and Chiesi Global Rare Diseases Announce U.S. Food and Drug Administration Acceptance of a Resubmitted Biologics License Application for Pegunigalsidase Alfa for the Proposed Treatment of Fabry Disease
Protalix BioTherapeutics, Inc. (NYSE American:PLX) (TASE:PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell based protein expression system, and Chiesi Global Rare Diseases, a business unit of the Chiesi Group established to deliver innovative therapies and solutions for people affected by rare diseases, today announced that the U.S. Food and Drug Administration (FDA)
